Risk of Developing IBD Can Be Predicted with Serum Biomarkers, Researchers Find

Risk of Developing IBD Can Be Predicted with Serum Biomarkers, Researchers Find
Findings from the PREDICTS study indicated that before symptoms appear, markers of Crohn's disease can be detected. The new discovery may help to predict risk not only of disease development but also of disease complications. The study, “Serologic microbial associated markers can predict Crohn's disease behaviour years before disease diagnosis,” was published in the journal Alimentary Pharmacology & Therapeutics. The research was conducted by CRADA (Cooperative Research and Development Agreement), a research collaboration between the Mayo Clinic, Mount Sinai Health System, Prometheus Laboratories, Janssen Pharmaceuticals, and the Naval Medical Research Center. "Acquiring mechanistic information on pre-clinical IBD [inflammatory bowel disease] can potentially uncover key pathogenic events, lead to the development of new therapeutic targets and inform predictive algorithms that could be used to define at-risk populations in whom to test these approaches," said Jean-Frédéric Colombel, M.D., co-senior author of the study and co-director of The Susan and Leonard Feinstein Inflammatory Bowel Disease Clinical Center at Mount Sinai, in a news release. "This study adds an additional piece of evidence into 'life before IBD,' a major focus of research at Mount Sinai, since exploring the pre-clinical phase of inflammatory bowel disease may offer some new insights in the origin of IBD and hopefully prevention," he said. The researchers evaluated the pattern of serologic anti-microbial antibodies prior to an IBD diagnosis, and the subsequent risk of complicated Crohn's disease at diagnosis. Sera from 100 U.S. military personnel with Crohn's disease were obtained from the Department of Defense Serum Repository. For each patient, four samples were obtained
Subscribe or to access all post and page content.